SCHEMBL4928512

SCHEMBL4928512

CCCCOc1ccc(-n2c(NCc3ccc(Cl)cc3)nc3ccc(Cl)cc32)cc1

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
KMT2A Q03164 1/20 0.46
P2RX3 P56373 1/20 0.46
CACNA2D1 P54289 2/20 0.46
TP53 P04637 3/20 0.44
MAPT P10636 2/20 0.44
PDE2A O00408 6/20 0.43
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
FAAH O00519 1/20 0.41
DRD2 P14416 1/20 0.40
TBXA2R P21731 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930067 0.96 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4933454 0.94 NPC1 (0.43) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4924591 0.92 NPC1 (0.41) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4930141 0.92 P2RX3 (0.46) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4926405 0.92 NPC1 (0.56) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4922200 0.91 P2RX3 (0.46) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
Hydrochloric Acid SCHEMBL4925649 0.91 NPC1 (0.55) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4930564 0.88 NPC1 (0.41) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4930135 0.88 P2RX3 (0.46) SMN1; SMN2NPC1RAB9AKMT2AP2RX3
SCHEMBL4929856 0.87 P2RX3 (0.46) SMN1; SMN2NPC1RAB9AKMT2AP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 SMN1; SMN2 4521/4885NPC1 1300/4885RAB9A 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.